DOCSLIB.ORG

With Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
With Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults Adv Ther (2017) 34:2466–2480 DOI 10.1007/s12325-017-0634-4 ORIGINAL RESEARCH Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults Tomohiro Kusawake . Martin den Adel . Dorien Groenendaal-van de Meent . Alberto Garcia-Hernandez . Akitsugu Takada . Kota Kato . Yoshiaki Ohtsu . Masataka Katashima Received: September 1, 2017 / Published online: October 26, 2017 Ó The Author(s) 2017. This article is an open access publication ABSTRACT single dose of midazolam (7.5 mg) and warfarin (25 mg). A drug interaction was considered to Introduction: Amenamevir is a nonnucleoside occur if the 90% confidence interval (CI) of the antiherpes virus compound available for treat- least squares geometric mean ratio (GMR) of ing herpes zoster infections. Four studies aimed amenamevir to the comparator was outside the to determine any potential interactions prespecified interval of 0.80–1.25. between amenamevir and ketoconazole, rifam- Results: Interactions were observed between picin, midazolam, or warfarin in healthy male amenamevir and ketoconazole, rifampicin, and participants. midazolam, but not between amenamevir and Methods: Two studies were open-label studies warfarin. After a single 400-mg dose of ame- that evaluated the effects of multiple doses of namevir, the GMRs of amenamevir plus keto- ketoconazole (400 mg) and rifampicin (600 mg) conazole or rifampicin versus amenamevir on the pharmacokinetics of a single oral dose of alone for Cmax and the area under the plasma amenamevir. The other two studies were ran- concentration–time curve from time zero to domized, double-blind, parallel-group studies infinity (AUCinf) were 1.30 (90% CI 1.17–1.45) that evaluated the effects of multiple doses of and 2.58 (90% CI 2.32–2.87), respectively, for amenamevir on the pharmacokinetics of a ketoconazole and 0.42 (90% CI 0.37–0.49) and 0.17 (90% CI 0.15–0.19), respectively, for Enhanced content To view enhanced content for this rifampicin. Following multiple doses of ame- article go to http://www.medengine.com/Redeem/ namevir (400 mg), the GMRs of midazolam plus C8CCF060639C490D. amenamevir versus midazolam alone for AUCinf and C were 0.53 (90% CI 0.47–0.61) and 0.63 T. Kusawake (&) max Astellas Pharma Global Development Inc., (90% CI 0.50–0.80), respectively. After a single Northbrook, IL, USA dose of warfarin, the (S)-warfarin and (R)-war- e-mail: [email protected] farin mean Cmax increased and mean AUCinf decreased in the presence of amenamevir; M. den Adel Á D. Groenendaal-van de Meent Á A. Garcia-Hernandez however, the 90% CIs of the GMRs for these Astellas Pharma Europe B.V., Leiden, The parameters remained within the predefined Netherlands limits. A. Takada Á M. Katashima Conclusion: These findings confirm that ame- Astellas Pharma Inc., Tokyo, Japan namevir (as a cytochrome P450 3A4 substrate) can interact with ketoconazole or rifampicin, K. Kato Á Y. Ohtsu Astellas Pharma Inc., Tsukuba, Japan and (as a cytochrome P450 3A4 inducer) can Adv Ther (2017) 34:2466–2480 2467 interact with midazolam; however, no interac- elimination pathway of amenamevir was hep- tion between amenamevir and (S)-warfarin was atic metabolism in animal studies (unpublished observed, indicating that amenamevir is not an data). In a study in healthy volunteers, urinary inducer of cytochrome P450 2C9. excretion as unchanged drug was approxi- Funding: Astellas Pharma. mately 10% [9]. In vitro data further clarified Trial registration: EudraCT2007-002227-33 the main elimination pathway; the metabolism (study 15L-CL-008), EudraCT2007-002228-14 of amenamevir is significantly correlated with (study 15L-CL-009), EudraCT2007-002761-13 marker-enzyme activities specific for the (study 15L-CL-010), and EudraCT2007-002779- cytochrome P450 (CYP) isozymes CYP2B6, 14 (study 15L-CL-018). CYP2C19, and CYP3A4/5 [10]. The strongest correlation was observed for CYP3A4/5 2 Keywords: Amenamevir; Drug–drug (r = 0.9236, p\0.0001), suggesting CYP3A4/ interactions; Ketoconazole; Midazolam; 5-mediated metabolism is the main pathway for Pharmacokinetics; Rifampicin; Safety; elimination of amenamevir. In addition, Varicella–zoster virus; Warfarin in vitro enzyme induction data indicated that amenamevir potentially induces CYP3A4 and CYP2C9 activities, with a weak potential for INTRODUCTION inducing CYP2C19 (unpublished data). Herpes zoster is a major disease of the elderly Varicella–zoster virus (VZV) is a human her- population, and patients often require con- pesvirus (HHV) that leads to the development of comitant medications for the treatment of two distinct diseases: varicella (chicken pox) as other comorbidities [11]. Therefore, it is the first episode and herpes zoster (shingles) as important to determine any potential interac- the recurrent episode [1]. VZV is neurotrophic tions between medications whose metabolism is and remains latent in dorsal sensory ganglia mediated by CYP3A4 and CYP2C9. after the initial infection [2]. Herpes zoster is a This article summarizes the results of four manifestation of the reactivation of latent VZV. drug–drug interaction phase 1 studies that It is relatively uncommon in immunocompe- investigated potential interactions between tent individuals younger than 40 years, but the amenamevir and ketoconazole (a strong CYP3A4 incidence of herpes zoster markedly increases in inhibitor), rifampicin (a strong CYP3A4 inducer), those older than 50 years [3]. While the inci- midazolam (a CYP3A4 substrate), and (S)-war- dence rate of developing herpes zoster is 6–8 per farin (a CYP2C9 substrate) in healthy adults. 1000 person-years at 60 years of age, the inci- dence rate in patients aged 80 years or older increases to 8–12 per 1000 person-years [3]. METHODS Nucleoside analogs such as acyclovir [4], valacyclovir [5], and famciclovir [6] have been Study Design approved for the treatment of herpes simplex virus 1, herpes simplex virus 2, and VZV infec- Each of the four drug–drug interaction studies tions. Although these drugs are used for the was conducted at a single study site in France by treatment of HHV infections, there is a medical the contract research organization SGS-Aster. need for therapies with improved antiviral Study 15L-CL-008 (EudraCT2007-002227-33) activity to provide more rapid and complete was conducted between October 17, 2007, and resolution of signs and symptoms. November 28, 2007, study 15L-CL-009 (Eu- Amenamevir (ASP2151) is a nonnucleoside draCT2007-002228-14) was conducted between antiherpes compound developed for the treat- October 19, 2007, and November 28, 2007, ment of VZV infections. Preclinical studies have study 15L-CL-010 (EudraCT2007-002761-13) indicated that amenamevir targets the viral was conducted between September 13, 2007, helicase–primase complex, which is essential for and November 17, 2007, and study 15L-CL-018 viral DNA replication [7, 8]. The main (EudraCT2007-002779-14) was conducted 2468 Adv Ther (2017) 34:2466–2480 between September 13, 2007, and December 3, respiratory, renal, hepatic, neurological, der- 2007. Two of the studies were open-label studies matological, psychiatric, or metabolic disorders, that evaluated the effects of multiple doses of as judged by the study investigator. Study ketoconazole (study 15L-CL-008) and rifampi- 15L-CL-018 excluded participants with a history cin (study 15L-CL-009) on the pharmacokinet- of and/or signs and symptoms of current ics of a single oral dose of amenamevir. The abnormal hemostasis or blood dyscrasia or other two studies were randomized, dou- abnormal prothrombin time (PT) or activated ble-blind, parallel-group studies that evaluated partial thromboplastin time at screening. the effects of multiple doses of amenamevir (200 and 400 mg) on the pharmacokinetics of a Dosing and Sampling Schedules single dose of midazolam (study 15L-CL-010) and a single dose of warfarin (study In study 15L-CL-008, participants received a 15L-CL-018). single oral dose of amenamevir (400 mg as two The study protocols were approved by the 200-mg tablets) on day 1, after which they institutional review boards at the study site underwent a 48-h washout period. They then ˆ ´ ´ [Hopital Ambroise-Pare, Secretariat du CPP Ile received ketoconazole orally (400 mg as two de France VIII, Laboratoire d’Anatomopatholo- 200-mg tablets) once daily on days 3–13, with a gie (studies 15L-CL-008 and 15L-CL-009) and second single dose of amenamevir (400 mg) ´ CPP Ile de France I, Secretariat du CPP Ile de administered in combination with ketocona- ˆ France I, Hopital Hotel-Dieu (studies zole on day 10. Blood samples for amenamevir 15L-CL-010 and 15L-CL-018)]. All procedures analysis were collected before dosing and followed were in accordance with the ethical 30 min and 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, and standards of the responsible committee on 36 h after dosing on day 1, before dosing on day human experimentation (institutional and 3, and before dosing and 30 min and 1, 1.5, 2, 3, national) and with the Helsinki Declaration of 4, 5, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, and 96 h 1964, as revised in 2000. Informed consent was after dosing on day 10. obtained from all participants for their being In study 15L-CL-009, participants received a included in the study. single oral dose of amenamevir (400 mg) on day 1 and underwent a 48-h washout period, Study Participants after which they received rifampicin orally (600 mg as two 300-mg tablets) once daily on All four studies enrolled healthy male adults (aged days 3–11, with a second single dose of ame- 18–55 years). Studies 15L-CL-008 and 15L-CL-009 namevir (400 mg) administered with rifampi- required participants to have a body weight of at cin on day 10. Blood samples for amenamevir least 60 kg but less than 100 kg and a body mass analysis were collected before dosing and index of at least 18 kg/m2 but less than 30 kg/m2.
Load more

Recommended publications
  • “Amenalief® Tab. 200Mg” in Japan
    News Release July 3, 2017 Maruho Co., Ltd. Maruho receives manufacturing and marketing approval for Anti-Herpes Virus Agent “Amenalief® Tab. 200mg” in Japan Osaka (Japan), July 3, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces that today it has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW), for anti-herpes virus agent “Amenalief® Tab. 200mg” (INN: amenamevir) (hereinafter referred to as “the product”) for the treatment of herpes zoster (shingles) in Japan. The product is an anti-herpes virus agent with a novel mechanism of action created by Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka). The product has been observed to inhibit the proliferation of the varicella-zoster virus (hereinafter VZV) by inhibiting the activity of the helicase-primase complex, which is essential for viral DNA replication. In August 2012, Maruho and Astellas agreed on a license agreement for the development and commercialization of the product in Japan, and Maruho has been progressing its development. Herpes zoster (shingles) is a disease caused by reactivation of the chickenpox VZV in latently-infected nerve ganglia. The main treatment for shingles is anti-herpes virus agents. The product is proven to be effective against VZV when administered once a day after meals. Also, since most of the product is excreted in feces, it is not necessary to adjust the dosage and administration according to creatinine clearance, an indicator of kidney function. Maruho hopes the product will contribute to the expansion of treatment options and improvement in adherence for the treatment of shingles in Japan.
    [Show full text]
  • Truvada (Emtricitabine / Tenofovir Disoproxil)
    Pre-exposure Prophylaxis (2.3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Recommended dose in HIV-1 uninfected adults: One tablet TRUVADA safely and effectively. See full prescribing information (containing 200 mg/300 mg of emtricitabine and tenofovir for TRUVADA. disoproxil fumarate) once daily taken orally with or without food. (2.3) TRUVADA® (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use Recommended dose in renally impaired HIV-uninfected Initial U.S. Approval: 2004 individuals: Do not use TRUVADA in HIV-uninfected individuals if CrCl is below 60 mL/min. If a decrease in CrCl is observed in WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH uninfected individuals while using TRUVADA for PrEP, evaluate STEATOSIS, POST-TREATMENT ACUTE EXACERBATION OF potential causes and re-assess potential risks and benefits of HEPATITIS B, and RISK OF DRUG RESISTANCE WITH USE OF continued use. (2.4) TRUVADA FOR PrEP IN UNDIAGNOSED HIV-1 INFECTION -----------------------DOSAGE FORMS AND STRENGTHS-------------------­ See full prescribing information for complete boxed warning. Tablets: 200 mg/300 mg, 167 mg/250 mg, 133 mg/200 mg, and 100 Lactic acidosis and severe hepatomegaly with steatosis, mg/150 mg of emtricitabine and tenofovir disoproxil fumarate . (3) including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (5.1) --------------------------------CONTRAINDICATIONS-----------------------------­ TRUVADA is not approved for the treatment of chronic Do not use TRUVADA for pre-exposure prophylaxis in individuals with hepatitis B virus (HBV) infection. Severe acute unknown or positive HIV-1 status. TRUVADA should be used in exacerbations of hepatitis B have been reported in patients HIV-infected patients only in combination with other antiretroviral coinfected with HIV-1 and HBV who have discontinued agents.
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • Which Drugs Are Most Effective for Recurrent Herpes Labialis?
    Evidence-based answers from the clinical inquiries Family Physicians Inquiries Network Eiko Tubridy, MD; Gary Kelsberg, MD Valley Family Residency Which drugs are most Program, Renton, Wash Leilani St Anna, MLIS, effective for recurrent AHIP University of Washington Health Sciences Libraries, herpes labialis? Seattle AssistanT EDITOR EvidEncE-basEd answEr Jon O. neher, MD Valley Family Residency daily oral acyclovir or vala- ing to the agent used: valacyclovir reduces Program, Renton, Wash A cyclovir may help prevent her- both healing time and duration of pain, pes simplex labialis (HSL) recurrences famciclovir reduces both in one dosage (strength of recommendation [SOR]: B, form but not another, and acyclovir reduces meta-analysis of randomized controlled only pain duration (SOR: B, single RCTs). trials [RCTs] with heterogeneous results). Several topical medications (acyclovir, No trials compare oral or topical treat- penciclovir, docosanol) modestly decrease ments for HSL outbreaks against each oth- healing time and pain duration—typically er. Oral antivirals modestly reduce healing by less than a day—and require multiple time and duration of pain, varying accord- doses per day (SOR: B, multiple RCTs). Evidence summary The authors of the meta-analysis noted A systematic review and meta-analysis of the that although 9 studies favored the use of an effectiveness of oral and topical nucleoside antiviral drug, only 4 showed statistically sig- antiviral agents to prevent recurrent HSL in nificant differences when compared with pla- immunocompetent people found 11 RCTs cebo, and none of them had a low risk of bias. with a total of 1250 patients that compared They concluded that the review supported us- an active drug against placebo.1 The medi- ing oral acyclovir and valacyclovir to prevent cations were topical 5% acyclovir, topical 1% recurrent HSL.1 penciclovir, and oral acyclovir, valacyclovir, or famciclovir in various doses.
    [Show full text]
  • Reference ID: 2998411
    • New onset or worsening renal impairment: Can include acute HIGHLIGHTS OF PRESCRIBING INFORMATION renal failure and Fanconi syndrome. Assess creatinine clearance These highlights do not include all the information needed to use (CrCl) before initiating treatment with COMPLERA. Monitor CrCl COMPLERA safely and effectively. See full prescribing and serum phosphorus in patients at risk. Avoid administering information for COMPLERA. COMPLERA with concurrent or recent use of nephrotoxic drugs. (5.3) COMPLERATM (emtricitabine/rilpivirine/tenofovir disoproxil • Caution should be given to prescribing COMPLERA with drugs fumarate) tablets that may reduce the exposure of rilpivirine. (5.4) Initial U.S. Approval: 2011 • Caution should be given to prescribing COMPLERA with drugs with a known risk of Torsade de Pointes. (5.4) WARNINGS: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE • Depressive disorders: Severe depressive disorders (depressed EXACERBATION OF HEPATITIS B mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation) have been See full prescribing information for complete boxed warning. reported. Immediate medical evaluation is recommended for severe depressive disorders. (5.5) • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of • Decreases in bone mineral density (BMD): Consider monitoring nucleoside analogs, including tenofovir disoproxil BMD in patients with a history of pathologic fracture
    [Show full text]
  • Comparable Efficacy with Entecavir Monotherapy and Tenofovir
    BMJ Open Gastroenterol: first published as 10.1136/bmjgast-2015-000030 on 31 December 2015. Downloaded from Hepatology Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients Sumbella Baqai,1 James Proudfoot,2 Ronghui Xu,3,4 Steve Kane,5 Margaret Clark,6 Robert Gish,7,8,9,10,11 To cite: Baqai S, Proudfoot J, ABSTRACT et al Summary box Xu R, . Comparable Objectives: The long-term goal for chronic hepatitis B efficacy with entecavir patients is to maintain viral suppression in order to monotherapy and tenofovir– What is already known about this subject? reduce disease progression risk. Because patients with entecavir combination in ▸ Finding effective therapy for patients with chronic hepatitis B patients. previous treatment failure may have multiple viral chronic hepatitis B virus (HBV) infection who BMJ Open Gastro 2015;2: resistance mutations, finding effective therapy is e000030. doi:10.1136/ challenging. Because recent studies have shown that have had previous treatment failure, many of bmjgast-2015-000030 the combination of entecavir and tenofovir is effective whom have multiple viral resistance mutations, in achieving virological response in many patients with is a challenge. prior treatment failure and multiple drug resistance ▸ Several recent studies have shown that combin- ation therapy with entecavir (ETV) and tenofovir Received 27 January 2015 mutations, we compared outcomes with this Revised 22 April 2015 combination versus monotherapy. (TDF) is effective in achieving virological by copyright. Accepted 30 April 2015 Methods: With a retrospective chart review we response in the majority of patients with prior compared results in 35 patients with previous treatment treatment failure and multiple drug resistance failure treated with the entecavir-tenofovir combination to mutations.
    [Show full text]
  • Herpes Simplex Virus
    HSV Herpes simplex virus HSV (Herpes simplex virus) can be spread when an infected person is producing and shedding the virus. Herpes simplex can be spread through contact with saliva, such as sharing drinks. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with ascab characteristic of herpetic disease. As neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. www.MedChemExpress.com 1 HSV Inhibitors (Z)-Capsaicin 1-Docosanol (Zucapsaicin; Civamide; cis-Capsaicin) Cat. No.: HY-B1583 (Behenyl alcohol) Cat. No.: HY-B0222 (Z)-Capsaicin is the cis isomer of capsaicin, acts 1-Docosanol is a saturated fatty alcohol used as an orally active TRPV1 agonist, and is used in traditionally as an emollient, emulsifier, and the research of neuropathic pain. thickener in cosmetics, and nutritional supplement; inhibitor of lipid-enveloped viruses including herpes simplex. Purity: 99.96% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 500 mg 2-Deoxy-D-glucose 20(R)-Ginsenoside Rh2 (2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose) Cat. No.: HY-13966 Cat. No.: HY-N1401 2-Deoxy-D-glucose is a glucose analog that acts as 20(R)-Ginsenoside Rh2, a matrix a competitive inhibitor of glucose metabolism, metalloproteinase (MMP) inhibitor, acts as a inhibiting glycolysis via its actions on hexokinase.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 33, No. 2, 2019 WHO Drug Information Contents Publication News 135 53rd report of the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) Consultation Documents 139 Concept Note: A Framework for Evaluating and Publicly Designating Regulatory Authorities as WHO-Listed Authorities 159 Quality Management System Requirements for National Inspectorates 174 Procedure for the Elaboration, Revision and Omission of Monographs and Other Texts for The International Pharmacopoeia 179 Good Chromatography Practices 194 Good Storage and Distribution Practices for Medical Products ATC/DD Classification 226 ATC/DDD Classification (Temporary) 229 ATC/DDD Classification (Final) International Nonproprietary Names (INN) 233 List No. 121 of Proposed International Nonproprietary Names (INN) for Pharmaceutical Substances Abbreviations and websites CHMP Committee for Medicinal Products for Human Use (EMA) EMA European Medicines Agency (www.ema.europa.eu) EU European Union FDA U.S. Food and Drug Administration (www.fda.gov) Health Canada Federal department responsible for health product regulation in Canada (www.hc-sc.gc.ca) HPRA Health Products Regulatory Authority, Ireland (www.hpra.ie) HSA Health Sciences Authority, Singapore (www.hsa.gov.sg) ICDRA International Conference of Drug Regulatory Authorities ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (www.ich.org) IGDRP International Generic Drug Regulators Programme (https://www.igdrp.com)
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • ATC/DDD Classification
    WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/ DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information. ATC/DDD classification (temporary) The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2018. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2019. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2020 version of the ATC/DDD Index. New ATC 5th level codes ATC level name/INN ATC code acalabrutinib L01XE51 amenamevir J05AX26 amlodipine and celecoxib C08CA51 arginine and lysine V03AF11 atorvastatin and omega-3 fatty acids C10BA08 baloxavir marboxil J05AX25 betrixaban B01AF04 brolucizumab S01LA06 cemiplimab L01XC33 crizanlizumab B06AX01 daclatasvir, asunaprevir and beclabuvir J05AP58 darolutamide L02BB06 elagolix H01CC03 elbasvir J05AP10 entinostat L01XX64 Continued 5 51 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018 New ATC 5th level codes (continued)
    [Show full text]
  • Report on the Deliberation Results June 7, 2017 Pharmaceutical
    Report on the Deliberation Results June 7, 2017 Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare Brand Name Amenalief Tab. 200 mg Non-proprietary Name Amenamevir (JAN*) Applicant Maruho Co., Ltd. Date of Application April 27, 2016 Results of Deliberation In its meeting held on May 30, 2017, the Second Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product. The re- examination period is 8 years. Neither the drug product nor its drug substance is classified as a poisonous drug or a powerful drug. Condition of Approval The applicant is required to develop and appropriately implement a risk management plan. *Japanese Accepted Name (modified INN) This English translation of this Japanese review report is intended to serve as reference material made available for the convenience of users. In the event of any inconsistency between the Japanese original and this English translation, the Japanese original shall take precedence. PMDA will not be responsible for any consequence resulting from the use of this reference English translation. Review Report May 8, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted by the Pharmaceuticals and Medical Devices Agency (PMDA). Brand Name Amenalief Tab. 200 mg Non-proprietary Name Amenamevir Applicant Maruho Co., Ltd. Date of Application April 27, 2016 Dosage Form/Strength Tablets: Each tablet contains 200 mg of Amenamevir.
    [Show full text]
  • Visible Spectrophotometric Determination of Famciclovir in Bulk and Pharmaceutical Dosage Formulations
    Asian Journal of Chemistry Vol. 19, No. 5 (2007), 3617-3620 Visible Spectrophotometric Determination of Famciclovir in Bulk and Pharmaceutical Dosage Formulations SYED NIZAMUDDIN*, DIVAKAR GOLI, Y.N. MANOHARA† and M.C. RAVI Department of Pharmaceutical Analysis Acharya & B.M. Reddy College of Pharmacy, Bangalore-560 090, India Tel: (91)9845121221 (M); E-mail: [email protected] Two simple colorimetric methods for the estimation of famciclovir in pharmaceutical dosage forms. In method A famciclovir undergoes complexation with SNP and to form coloured chromogen exhibiting absorption maximum at 428 nm and obeyed Beer's law in the concentration range of 2-12 µg/mL. In the method B based on the formation of an ion pair with bromocresol green in acidic medium and the subse- quent extraction of the ion pair in chloroform. The yellow coloured ion pair showed an absorption maximum at 421 nm with apparent molar absorptivity. The proposed methods gave reproducible results for the estimation of famciclovir from its pharmaceutical formulation. Key Words: Spectrophotometric analysis, Famciclovir. INTRODUCTION Famciclovir is chemically 2-[2-(2-amino-9H-purin-9-yl)ethyl] trim- ethylene diacetate1,2 is an acyclic guanine nucleoside analogue. It is a new generation antiviral drug which is active in vitro and in vivo against herpes simplex virus types 1 and 2 and against varicella-zoster virus3-6. It is not official in any Pharmacopoeia. A few analytical methods have been re- ported for its quantitative estimation in pharmaceutical formulations that include estimation in plasma and urine by HPLC7 and UV8 spectrophoto- metric estimation in methanol. The present work describes two spectro- photometric methods for the estimation of famciclovir in its formulations.
    [Show full text]